Midgard Science

Labs / Assays & in vitro testing

IRBM

Pomezia, Italy · irbm.com

AAALAC · GLP

On your own

Free. Their own form.

Contact IRBM directly

Through Midgard

Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.

Request a quote through Midgard

IRBM is a drug discovery research organization in Pomezia, near Rome, Italy. It supports programs from target validation through preclinical candidate selection across small molecules, peptides, antibodies, and cell therapy, serving pharmaceutical companies, biotech firms, foundations, and other research partners. Its work covers chemistry, biology, DMPK, in vivo pharmacology, structural biology, and specialized disease-area assays.

Their website has a general contact form; we send your quote request through it.

What they offer

  • Integrated drug discovery projects

    Runs coordinated programs from target validation through preclinical candidate selection on a single site with one team.

  • Small molecule discovery

    Advances small molecule programs from screening hits to preclinical candidates.

  • Medicinal chemistry

    Designs, makes, tests, and analyzes compounds through iterative DMTA cycles to optimize chemical series.

  • Synthetic chemistry

    Develops synthetic routes, parallel synthesis, scale-up, and purification to produce target compounds and libraries.

  • Computational chemistry

    Uses structure-based and ligand-based in silico methods to support target analysis, hit identification, hit-to-lead, and lead optimization.

  • Peptide discovery

    Develops peptide programs from starting sequence to candidate, including macrocyclic, complex, and protein peptides.

  • Antibody discovery

    Identifies, characterizes, and validates monoclonal antibodies.

  • Display technologies

    Provides peptide phage display, antibody phage display, and mRNA display for discovery workflows.

  • Assay development

    Builds assays for target validation and screening workflows.

  • High throughput screening

    Screens compound collections at scale to identify starting points for discovery programs.

  • High content screening

    Applies image-based screening to support hit identification and biology-driven decision making.

  • Biophysical approaches

    Uses biophysical methods to support characterization and discovery decisions.

  • Functional genomics

    Supports target identification and validation with genomics-based studies.

  • Protein production

    Produces proteins to support structural biology and assay work.

  • NMR

    Uses NMR platforms for structural characterization and drug discovery support.

  • DMPK

    Provides ADME, pharmacology, PK/PD, bioanalytics, and biotransformation studies.

  • In vivo pharmacology

    Evaluates compounds in in vivo pharmacology studies.

  • Spatial biology

    Offers spatial biology support within therapeutic area programs.

  • Bioinformatics

    Provides bioinformatics support for therapeutic area programs and discovery workflows.

What they work on

Modalities
Small molecule, Antibody, Peptide, mRNA, Cell therapy, Recombinant protein
Species and models
CAR-T, patient-derived models, Zika virus NS2B-NS3 protease
Assays and studies
assay development, high throughput screening, high content screening, biophysical approaches, functional genomics, HTT assays, blood brain barrier assay
Instruments and platforms
400 MHz spectrometer, 500 MHz Bruker spectrometer, 600 MHz Bruker spectrometer, Biotage purification stations, HPLC, mass spectroscopy instruments, UPLC
Scale and capacity
compound collection of more than 400,000 high quality molecules, single research hub in Rome, Italy
Therapeutic areas
Oncology, Immuno-oncology, Spatial biology, Infectious disease, Neuroscience, Hepatitis B, Rare diseases, Viral disease, Cardiovascular disease, Metabolic disease, Neurodegenerative disorders, Ophthalmology, and 2 more
Turnaround
results become a decision within days
What to send
target hypothesis and the disease context behind it · a validated target and an assay ready to run at scale · compound collections · confirmed hit · sequence
Type
CRO
Sites
Pomezia (Rome), Italy · Rome, Italy
Quality
Code of Ethics · Policies and Certifications · Environmental, Health and Safety Policy · Energy Policy · Diversity and Inclusion Policy · Gender Equality Policy
Serves
Italy, Europe, worldwide
Founded
2019

Similar labs. Venenum Biodesign, Aurigene Pharmaceutical Services, Evotec, EyeCRO

Found in a contract services directory. Listing built from irbm.com. Work here? Claim this listing.

IRBM · Midgard Science